Alaunos Therapeutics
TCRT
45 hedge funds and large institutions have $4.23M invested in Alaunos Therapeutics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 44 closing their positions.
17,600% more call options, than puts
Call options by funds: $177K | Put options by funds: $1K
42% more capital invested
Capital invested by funds: $2.97M → $4.23M (+$1.26M)
1.35% more ownership
Funds ownership: 0.11% → 1.46% (+1.3%)
45% less funds holding
Funds holding: 82 → 45 (-37)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
82% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$30.9K |
| 2 |
FGA
Fortis Group Advisors
Westwood,
New Jersey
|
+$28K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$26K |
| 4 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$22.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$11.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$283K |
| 2 |
Squarepoint
New York
|
-$31.6K |
| 3 |
Morgan Stanley
New York
|
-$31K |
| 4 |
Renaissance Technologies
New York
|
-$27K |
| 5 |
Two Sigma Investments
New York
|
-$21.3K |
TCRT Hedge Fund Activity: Q1 2024 in Review
45 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2024, worth a combined $4.23M — up 42% from $2.97M a quarter earlier.
Sellers outnumbered buyers: 44 funds closed out of TCRT and 8 opened new positions — a net loss of 36 holders — while 12 trimmed existing stakes and 5 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $30.9K. The largest seller was Discovery Capital Management, exiting entirely with an estimated $283K sold.
- 45 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2024, down from 82 in Q4 2023.
- Funds reported $4.23M of Alaunos Therapeutics stock for Q1 2024, up 42% quarter-over-quarter.
- 8 funds opened new Alaunos Therapeutics positions in Q1 2024 and 44 closed out, a net change of -36 holders.
- The largest Alaunos Therapeutics buyer in Q1 2024 was Virtu Financial, an estimated $30.9K added.
- The largest Alaunos Therapeutics seller in Q1 2024 was Discovery Capital Management, an estimated $283K sold.
Based on aggregated 13F filings for Q1 2024.